PDCD1 and hepatocellular carcinoma: We therefore explored the potential of a sequential combination therapy approach using ropeg at a high dose level of 450 μg followed by an anti-PD-1 therapeutic antibody as an adjuvant therapy in HBV-related HCC [19].